Best ASX 200 Shares of The Year: Who Tops The FY26 List?
The article reviews ASX 200 top performers over the past year, noting the index was about 1.5% higher over the period and YTD total return around -3.30 points. 4DMedical led with a 1,787% gain to $4.53, after FDA 510(k) clearance and adoption by major US hospitals. Materials dominated gains, including lithium, gold, rare earths and copper miners; it also cites Electro Optic Systems’ ~$80m laser order and other industrials’ contract wins.
How this was made
The 30-second read
Why it matters
It highlights a concrete regulatory/product adoption story for 4DMedical and a specific defense export order for Electro Optic Systems, while most other names are explained via commodity price rebounds and policy narratives.
Market read
Useful for mapping which themes (U.S. healthcare adoption, defense procurement, lithium/copper/gold policy and price cycles) traders are emphasizing, but it is not a fresh catalyst feed for most names.
What to watch
For most tickers, the text provides price-performance and sector tailwinds but not company-specific incremental catalysts; traders may need to verify whether any of the cited events are already fully priced.
Background
The piece reviews ASX 200’s top performers over the past year and discusses what it says drove those moves into FY27.
Ticker impact
BHP is described as benefiting from a strategic shift that saw shares add 50% and $100bn in market cap, per the article.
Limited incremental edge from this article alone; follow-through depends on whether the strategic shift has further disclosed details.
The article references a “strategic shift” but does not specify what changed or provide new BHP facts.
Electro Optic Systems is cited for a world-first export order: a 100-kilowatt high-energy laser weapon system to South Korea (~US$80m) with delivery in 2027.
Positive bias if traders believe delivery/order execution risk is manageable; volatility around defense procurement headlines.
The article provides contract value, customer geography, and delivery timing, which are actionable for expectations even if not same-day.
SRG Global is cited as up 137% to $3.98, attributed to multi-year construction and maintenance demand from mining/infrastructure expansion.
Likely correlated with broader capex sentiment; risk of mean reversion if expectations outrun fundamentals.
Performance is cited, but the article lacks a discrete SRG catalyst.
Market effects
Materials/commodities and defense/industrial services are portrayed as the dominant return drivers; reversals in lithium/copper/gold would likely pressure the same cohort.
ASX 200 performance narrative is tied to global commodity pricing and U.S. healthcare adoption for the medical imaging outlier.
U.S. FDA clearance and named U.S. hospital adoption for 4DMedical links Australian equities to U.S. healthcare procurement and reimbursement dynamics.
Counterpoint
The article is a winners recap with limited new disclosures; large prior gains may mean crowded positioning and higher downside if macro/commodity assumptions fade.
Key entities
- company4DMedical
CT:VQ software cleared by FDA (510(k)) and adopted by multiple U.S. hospital systems, per the article.
- companyElectro Optic Systems
Export order for a 100-kilowatt high-energy laser weapon system to South Korea (~US$80m), delivery in 2027, per the article.
- companyElevra Lithium
North American lithium mine expansion update citing a 102% increase in project NPV and accelerated timelines, per the article.
